autologous BCMA-directed CAR T-cells

Developed for: plasma cell myeloma
Investigated by: Affiliated Hospital of Jiangnan University · Changshu Frist People's Hospital · Jiangsu Province Hospital of Traditional Chinese Medicine · Jiangyin People's Hospital · Jingjiang People's Hospital · Lianyungang Hospital Affiliated Bengbu Medical College
+8 more
· Nanjing Medical University · Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd · Suzhou Municipal Hospital · The First Affiliated Hospital of Soochow University · The First Affiliated Hospital with Nanjing Medical University · The Second People's Hospital of Huai'an · The Third People's Hospital of Kunshan · Zhangjiagang First People's Hospital

today NCT04287660 · Ph 3

2018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT04287660	Oct 2017 → Jan 2023	plasma cell myeloma	The First Affiliated Hospital of Soochow University	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	autologous BCMA-directed CAR T-cells	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04287660 ↗
Modality	Cell therapy	“autologous BCMA-directed CAR T-cells” NCT04287660 ↗
Route	Intravenous	“BCMA CAR T cell: (2-3)×10E7/kg, intravenously infusion.” NCT04287660 ↗